A double-blind trial of 153 women with early-onset preeclampsia found that 600 mg/day of N-acetylcysteine did not significantly delay progression to severe disease — casting doubt on hopes for a low-cost option in resource-limited settings.
- 2026-06-17
- RCT
- n = 153
- PloS one
This is one of the first randomized trials testing NAC for this condition; the null result suggests it is not effective in this population, but the body of evidence is still too thin to draw a final conclusion.